Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy

Aim . To investigate whether tumor size is a reasonable indication for adjuvant chemotherapy for T3-4aN0M0 gastric cancer patients after D2 gastrectomy. Method. We performed a retrospective study of 269 patients with a histological diagnosis of T3-4aN0M0 stage gastric cancer who underwent D2 radical...

Full description

Saved in:
Bibliographic Details
Published in:Gastroenterology research and practice 2017-01, Vol.2017 (2017), p.1-9
Main Authors: Peng, Jun-Sheng, Zhou, Zhi-Wei, Xiang, Jun, Li, Yuan-Fang, Nie, Run-Cong, Ou-Yang, Li-Ying, Chen, Shi, Chen, Ying-Bo
Format: Article
Language:English
Subjects:
Cancer therapies
Chemotherapy
Chinese medicine
Clinical trials
Gastric cancer
Hospitals
Lymphatic system
Medical prognosis
Metastasis
Patients
Surgery
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim . To investigate whether tumor size is a reasonable indication for adjuvant chemotherapy for T3-4aN0M0 gastric cancer patients after D2 gastrectomy. Method. We performed a retrospective study of 269 patients with a histological diagnosis of T3-4aN0M0 stage gastric cancer who underwent D2 radical surgery at the Sun Yat-sen University Cancer Center or the Sixth Affiliated Hospital of Sun Yat-sen University between January 2006 and December 2010. The follow-up lasted until June of 2015. Chi-square tests and Kaplan-Meier methods were employed to compare the clinicopathological variables and prognoses. Result. For this group of patients, univariate analyses revealed that tumor size (p
ISSN:1687-6121
1687-630X
DOI:10.1155/2017/4928736